| Powder: | Yes |
|---|---|
| Customized: | Non-Customized |
| Certification: | GMP, HSE, ISO 9001, USP, BP |
| Suitable for: | Elderly, Children, Adult |
| State: | Powder |
| Purity: | >99% |
| Samples: |
|---|
| Customization: |
|---|
Suppliers with verified business licenses
Audited Supplier 
| Product Name | Factory Supply API Powder CAS 872365-14-5 99% Fevipiprant |
| Appearance | White powder |
| Molecular formula | C19H17F3N2O4S |
| Molecular weight | 426.41 |
| Keywords | Powder Fevipiprant ,Price Fevipiprant; Pure Fevipiprant |
| Shelf Life | 24 months when properly stored |
| Storage | Keep in a cool, dry, dark location |
What is Fevipiprant
Fevipiprant (INN; code name QAW039) is a drug being developed by Novartis which acts as a selective, orally available antagonist of the prostaglandin D2 receptor 2 (DP2 or CRTh2). It was initially researched as a treatment for allergies and inflammatory disorders, particularly asthma, but despite being well-tolerated in clinical trials and showing reasonable efficacy against allergen-induced airway responses in asthmatic patients, it failed to show sufficient advantages over existing drugs and was discontinued from further development in this application.
Fevipiprant, also known as NVP-QAW039 or QAW039, is an oral active and potent CRTh2 receptor antagonist and potentially useful for asthma treatment. [(3)H]-QAW039 displayed high affinity for the human CRTh2 receptor (1.14 ± 0.44 nM) expressed in Chinese hamster ovary cells, the binding being reversible and competitive with the native agonist prostaglandin D2(PGD2). QAW039 was also a potent inhibitor of PGD2-induced cytokine release in human Th2 cells. Fevipiprant reduces eosinophilic airway inflammation and is well tolerated in patients with persistent moderate-to-severe asthma and raised sputum eosinophil counts despite inhaled corticosteroid treatment. Fevipiprant demonstrates a favorable safety profile.
Suppliers with verified business licenses
Audited Supplier 
){kind=link}
){kind=link}